Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer

Stephen E. Jones, Pankaj Khandelwal, Kristi McIntyre, Robert Mennel, Douglas Orr, Robert Kirby, Edward Agura, Lewis Duncan, William Hyman, Tammy Roque, David Regan, Michael Schuster, Nikolay Dimitrov, Leslie Garrison, Mary Lange

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences